France Pharmaceuticals & Healthcare Report

Providing expert analysis, independent forecasts and competitive intelligence on the pharmaceuticals and healthcare industry.

Report includes: BMI Industry View, Industry SWOT Analysis, Industry Forecasts, BMI's Pharmaceuticals and Healthcare Risk Reward Index, Market Summary, Economic Forecasts, Company Profiles and Competitive Landscape.

Why you should buy this report

  • Benefit from the latest market opportunities
  • Understand the threats to your operations and investments and protect your company against future risks
  • Gain insight on emerging trends that could support, strengthen or disrupt your activities in the market
  • Get a full view of the competitive landscape to assess your market position
×

Sign up to download the France Pharmaceuticals & Healthcare Report

By submitting this form you are acknowledging that you have read and understood our Privacy Policy.

Thank you for your interest

You will shortly receive your free executive summary by email.

France Pharmaceuticals & Healthcare Report
Product Price
$1,295.00

BMI View: The UK vote to leave the EU will weigh on France ' s economic growth over the next few quarters, which in turn will pose downside risks to our pharmaceutical and healthcare sector forecasts. De spite the large pharmaceutical market and high drug spending per capita, which will continue to make France a major global market for drugmakers, market expansion will only resume at a slow pace over the next few years, with return to marginal positive growth in 2017. In line with our view in recent quarters, the rate of investment growth in France ' s pharmaceutical sector has remained relatively subdued in H116, while this trend will likely continue over the coming quarters, in part due to sluggish labo u r market reform.

Headline Expenditure Projections

  • Pharmaceuticals: EUR33.46bn (USD37.11bn) in 2015 to EUR33.34bn (USD35.68bn) in 2016; -0.3% in local currency terms and -3.9% in US dollar terms. Forecast broadly in line with last quarter.

  • Healthcare: EUR251.26bn (USD278.66bn) in 2015 to EUR257.25bn (USD275.26bn) in 2016; +2.4% in local currency terms and -1.2% in US dollar terms. Forecast revised downwards from last quarter.

Headline Pharmaceuticals & Healthcare Forecasts (France 2014-2020)
2014 2015 2016f 2017f 2018f 2019f 2020f
f = BMI forecast. Source: WHO, National Sources, BMI
Pharmaceutical sales, USDbn 44.700 37.110 35.680 36.730 38.690 40.950 41.740
Pharmaceutical sales, % of GDP 1.58 1.53 1.50 1.46 1.43 1.40 1.38
Pharmaceutical sales, % of health expenditure 13.7 13.3 13.0 12.7 12.4 12.2 12.0
Health spending, USDbn 326.480 278.660 275.260 290.400 312.530 336.750 348.540

Risk/Reward Index

In Q416, France's Risk/Reward Index (RRI) score remains unchanged at 73.1 out of the maximum 100 points. France is ranked sixth in terms of market attractiveness to pharmaceutical investors out of the 15 markets in Western Europe covered by BMI's RRI matrix. France's score is boosted by the large multi-billion dollar drug market and large pensionable population, but dragged down by modest market expansion.

Latest Updates

  • In July 2016, Sanofi and Boehringer Ingelheim announced the signing of contracts to secure the strategic transaction initiated in December 2015 which consists of an exchange of Sanofi's animal health business and Boehringer Ingelheim's consumer healthcare business. The transaction is expected by year-end 2016.

  • Stellar Biotechnologies and Neovacs are to form Neostell, a simplified stock corporation headquartered in France that will carry out the business of the companies' joint venture (JV) to manufacture and sell conjugated therapeutic vaccines using Stellar's Keyhole Limpet Hemocyanin (KLH) in the niche market of systemic lupus.

  • Also in July, according to the timetable set by the law of modernisation of France's health system, Hospital Grouping by Territories (GHT), a new mode of cooperation and integration of public health services across a territory, were formally established throughout France.

  • In the same month, France's Minister of Health Marisol Touraine launched a national strategy under the concept of 'e-health 2020' that will seek to enable making appointments and payments online, simplifying procedures for patients, enhancing tele-monitoring and telemedicine and the use of Big Data in diagnosis, among other objectives.

  • Valneva announced that it has successfully generated a highly purified inactivated vaccine candidate against the Zika virus in July 2016, an early advantage in development that will give Valneva options for acquisition or partnership with a larger company.

BMI Economic View

France's fragile economic recovery will falter in 2017 on the back of weak UK demand and plummeting confidence levels domestically. French exporters and fixed investment will take the biggest hit.

BMI Political View

Following the Brexit vote, France's political landscape in the run-up to the presidential elections in April 2017 will become increasingly polarised, with parties on both the far left and right calling to change Paris' relations with Brussels.

BMI Industry View
7
Table: Headline Pharmaceuticals & Healthcare Forecasts (France 2014-2020)
7
SWOT
9
Industry Forecast
11
Pharmaceutical Market Forecast
11
Table: Pharmaceutical Sales, Historical Data And Forecasts (France 2012-2020)
13
Healthcare Market Forecast
15
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (France 2012-2020)
18
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (France 2012-2020)
19
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (France 2012-2020)
19
Prescription Drug Market Forecast
20
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (France 2012-2020)
21
Patented Drug Market Forecast
22
Table: Patented Drug Market Indicators, Historical Data And Forecasts (France 2012-2020)
23
Generic Drug Market Forecast
24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (France 2012-2020)
26
OTC Medicine Market Forecast
27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (France 2012-2020)
29
Pharmaceutical Trade Forecast
30
Table: Pharmaceutical Trade Data And Forecasts (France 2014-2020)
32
Table: Pharmaceutical Trade Data And Forecasts local currency (France 2014-2020)
32
Industry Risk/Reward Index
33
Western Europe Risk/Reward Index
33
France Risk/Reward Index
38
Rewards
38
Risks
38
Regulatory Review
40
Intellectual Property Issues
42
Pricing & Reimbursement Regime
43
Table: France Reimbursement Categories
44
Market Overview
53
Healthcare Sector
54
Table: Projected Regional Ranking Of Physicians, 2017
60
Table: Healthcare Personnel (France 2010-2015)
61
Table: Healthcare Activity (France 2010-2015)
61
Table: Healthcare Resources (France 2010-2015)
62
Research & Development
63
Clinical Trials
67
Epidemiology
69
Competitive Landscape
71
Research-Based Industry
71
Table: Table: Multinational Market Activity
73
Generic Drugmakers
74
Pharmaceutical Distribution
75
Pharmaceutical Retail Sector
76
Company Profile
78
GlaxoSmithKline
78
Ipsen
81
Merck & Co
85
Novartis
88
Sanofi
91
Servier
99
Demographic Forecast
103
Table: Population Headline Indicators (France 1990-2025)
104
Table: Key Population Ratios (France 1990-2025)
104
Table: Urban/Rural Population & Life Expectancy (France 1990-2025)
105
Table: Population By Age Group (France 1990-2025)
105
Table: Population By Age Group % (France 1990-2025)
106
Glossary
108
Methodology
110
Pharmaceutical Expenditure Forecast Model
110
Healthcare Expenditure Forecast Model
110
Notes On Methodology
111
Risk/Reward Index Methodology
112
Index Overview
113
Table: Pharmaceutical Risk/Reward Index Indicators
113
Indicator Weightings
114

The France Pharmaceuticals & Healthcare Report features BMI Research's forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's France Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the France pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's pharmaceutical and healthcare market forecasts for France, to test other views - a key input for successful budgeting and strategic business planning in the French pharmaceutical and healthcare market.
  • Target business opportunities and risks in the French pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in France.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.

Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:

  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.

BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.